Literature DB >> 22001418

Obstetric antiphospholipid syndrome.

Claudio Galarza-Maldonado1, Maria R Kourilovitch, Oscar M Pérez-Fernández, Mariana Gaybor, Christian Cordero, Sonia Cabrera, Nikolai F Soroka.   

Abstract

Antiphospholipid syndrome (APS) in pregnancy has a serious impact on maternal and fetal morbidity. It causes recurrent pregnancy miscarriage and it is associated with other adverse obstetric findings like preterm delivery, intrauterine growth restriction, preeclampsia, HELLP syndrome and others. The 2006 revised criteria, which is still valid, is used for APS classification. Epidemiology of obstetric APS varies from one population group to another largely due to different inclusion criteria and lack of standardization of antibody detection methods. Treatment is still controversial. This topic should include a multidisciplinary team and should be individualized. Success here is based on strict control and monitoring throughout pregnancy and even in the preconception and postpartum periods. Further research in this field and unification of criteria are required to yield better therapeutic strategies in the future. Copyright Â
© 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22001418     DOI: 10.1016/j.autrev.2011.10.006

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  15 in total

1.  Pregnancy Outcome in Women with Obstetric and Thrombotic Antiphospholipid Syndrome-A Retrospective Analysis and a Review of Additional Treatment in Pregnancy.

Authors:  Karoline Mayer-Pickel; Katharina Eberhard; Uwe Lang; Mila Cervar-Zivkovic
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

Review 2.  HELLP syndrome and its relation with the antiphospholipid syndrome.

Authors:  Antonella Tufano; Antonio Coppola; Giuseppe M Maruotti; Pasquale Martinelli; Anna M Cerbone; Giovanni Di Minno
Journal:  Blood Transfus       Date:  2013-11-15       Impact factor: 3.443

Review 3.  Antibodies Against Complement Components: Relevance for the Antiphospholipid Syndrome-Biomarkers of the Disease and Biopharmaceuticals.

Authors:  Mirjana Bećarević
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

4.  The haplotype M2 of the ANXA5 gene is not associated with antitrophoblast antibodies.

Authors:  Nina Rogenhofer; Laura Engels; Nadja Bogdanova; Frank Tüttelmann; Arseni Markoff; Christian J Thaler
Journal:  J Assist Reprod Genet       Date:  2013-03-27       Impact factor: 3.412

Review 5.  TNF-alpha and annexin A2: inflammation in thrombotic primary antiphospholipid syndrome.

Authors:  Mirjana Bećarević
Journal:  Rheumatol Int       Date:  2016-10-04       Impact factor: 2.631

6.  Anti-phospholipid antibody syndrome occurrence in patients with persistent anti-phospholipid antibodies.

Authors:  Hyeok Choi; Sung Soo Ahn; Jason Jungsik Song; Yong-Beom Park; Jaewoo Song; Sang-Won Lee
Journal:  Rheumatol Int       Date:  2019-05-10       Impact factor: 2.631

Review 7.  Obstetric Anti-phospholipid Syndrome: State of the Art.

Authors:  Maria Chiara Gerardi; Melissa Alexandre Fernandes; Angela Tincani; Laura Andreoli
Journal:  Curr Rheumatol Rep       Date:  2018-08-13       Impact factor: 4.592

Review 8.  Treatment of the antiphospholipid syndrome.

Authors:  Monica Galli
Journal:  Auto Immun Highlights       Date:  2013-12-22

Review 9.  Antiphospholipid Antibodies and Antiphospholipid Syndrome during Pregnancy: Diagnostic Concepts.

Authors:  Roger A Levy; Flavia Cunha Dos Santos; Guilherme R de Jesús; Nilson R de Jesús
Journal:  Front Immunol       Date:  2015-05-07       Impact factor: 7.561

Review 10.  Obstetrical antiphospholipid syndrome: from the pathogenesis to the clinical and therapeutic implications.

Authors:  T Marchetti; M Cohen; P de Moerloose
Journal:  Clin Dev Immunol       Date:  2013-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.